Cellectis given another shot at off-the-shelf CAR-T
pharmafile | November 8, 2017 | News story | Medical Communications, Research and Development | CAR-T, biotech, cellectis, drugs, pharma, pharmaceutical
It is easy to forget the very real dangers that CAR-T treatment present to patients after Novartis and Gilead both successfully scored approvals on the back of impressive data, and with Juno Therapeutics recently posted potential best-in-class statistics in a recent trial.
The lesson though is in Juno Therapeutics’ previous CAR-T candidate, the one tested before its most recent promising Phase 2 results. The prior candidate JRA015 had resulted in the deaths of three patients causing a halt to be called on the trial, days later the FDA gave the company permission to begin again – only for another two individuals to suffer serious problems and to die as a result of the treatment.
This would explain why the FDA is being very cautious with how Cellectis manages its reopened Phase 1 clinical trial testing its UCART123 treatment. Working with the FDA, Cellectis announced five stipulations that the company will follow in order to begin the trial again:
- Decrease of the cohort dose level to 6.25×104 UCART123 cells/kg
- Decrease of the cyclophosphamide dose of the lympho-depleting regimen to 750 mg/m²/day over three days with a maximum daily dose of 1.33 grams of cyclophosphamide
- Inclusion of specific criteria at Day 0, the day of UCART123 infusion, such as no new uncontrolled infection after receipt of lymphodepletion, afebrile, off all but replacement dose of corticosteroids, no organ dysfunction since eligibility screening
- Provision to ensure that the next three patients to be treated in each protocol will be under the age of 65
- Provision to ensure that the enrolment will be staggered across the UCART123 protocols AML123 and ABC123: at least 28 days should elapse between the enrolments of two patients across the two studies
The fourth point seems to have been included to ensure that the company avoids repeating the scenario that led to the death of a 78-year-old man in the first stage of the trial; questions were raised regarding the wisdom of trialling a patient of such an age at such an early stage of clinical trials.
There is some hope that a CAR-T treatment that can avoid the autologous therapy required to extract a patients’ T cells in order to manufacture the therapy could drastically reduce the cost.
In Cellectis treatment, the T cells are donor-derived rather than taken from individual patients – allowing for a much faster production of the therapy.
Shares in the company spiked initially on the release of the news, before settling at 30 cents higher than before the announcement.
Ben Hargreaves
Related Content
AstraZeneca and Cellectis to collaborate for cell therapy and genomic medicine development
AstraZeneca has announced a collaboration and investment agreement with Cellectis for the development of next …
FDA approves IMIDEX’s AI-powered device VisiRad XR
The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …
Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo
On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …
